12 West Capital Management LP Increased Its Position in Alnylam Pharmaceuticals (ALNY) by $36.68 Million; Verisign (VRSN) Holder Boothbay Fund Management Has Lifted Its Position by $343,212 as Share Value Rose

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Logo

Boothbay Fund Management Llc increased its stake in Verisign Inc (VRSN) by 110.85% based on its latest 2018Q4 regulatory filing with the SEC. Boothbay Fund Management Llc bought 2,319 shares as the company’s stock rose 13.46% with the market. The institutional investor held 4,411 shares of the technology company at the end of 2018Q4, valued at $654,000, up from 2,092 at the end of the previous reported quarter. Boothbay Fund Management Llc who had been investing in Verisign Inc for a number of months, seems to be bullish on the $22.64B market cap company. The stock increased 0.04% or $0.07 during the last trading session, reaching $189.6. About 417,859 shares traded. VeriSign, Inc. (NASDAQ:VRSN) has risen 53.73% since April 15, 2018 and is uptrending. It has outperformed by 49.36% the S&P500. Some Historical VRSN News: 26/04/2018 – VERISIGN 1Q REV. $299M, EST. $298.0M; 15/05/2018 – S&P REVISES VERISIGN INC. TO RATING ‘BBB-‘ FROM ‘BB+’; OUTLOOK ‘STABLE’

12 West Capital Management Lp increased its stake in Alnylam Pharmaceuticals Inc (ALNY) by 225.94% based on its latest 2018Q4 regulatory filing with the SEC. 12 West Capital Management Lp bought 509,500 shares as the company’s stock rose 8.95% with the market. The hedge fund held 735,000 shares of the health care company at the end of 2018Q4, valued at $53.59 million, up from 225,500 at the end of the previous reported quarter. 12 West Capital Management Lp who had been investing in Alnylam Pharmaceuticals Inc for a number of months, seems to be bullish on the $9.56 billion market cap company. The stock increased 1.94% or $1.71 during the last trading session, reaching $89.81. About 787,295 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has declined 28.65% since April 15, 2018 and is downtrending. It has underperformed by 33.02% the S&P500. Some Historical ALNY News: 20/04/2018 – Dicerna Pharmaceuticals Announces Settlement of All Litigation with Alnylam; 08/05/2018 – ALNYLAM PHARMACEUTICALS INC – COMPANY EXPECTS FIRST CNS-TARGETED DEVELOPMENT CANDIDATE IN 2018; 10/04/2018 – Alnylam at Deutsche Bank Health Care Conference May 8; 11/05/2018 – Meadow Creek Adds Alnylam, Exits Spirit Air: 13F; 03/04/2018 – ALNYLAM PHARMA – WILL BE REQUIRED TO PROVIDE INITIAL PAYMENT TO COVER RAW MATERIAL PURCHASES AND RESERVE APPROPRIATE RESOURCES UNDER AGREEMENT; 03/04/2018 – ALNYLAM PHARMA – AGREEMENT HAS INITIAL TERM OF 5 YEARS, WHICH IS SUBJECT TO AUTOMATIC RENEWAL TERMS OF 2 YEARS; 28/03/2018 – Alnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis; 23/04/2018 – Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc02, a Subcutaneously Delivered; 20/04/2018 – DICERNA PHARMACEUTICALS – SETTLEMENT ALLOWS CO TO ADVANCE ALL KEY, PLANNED PIPELINE PROGRAMS; 24/04/2018 – Alnylam Pharmaceuticals: Apollo Study for Patients With Hereditary ATTR Amyloidosis

Boothbay Fund Management Llc, which manages about $486.48 million and $686.17 million US Long portfolio, decreased its stake in Owens Rlty Mtg Inc (NYSEMKT:ORM) by 27,536 shares to 57,377 shares, valued at $1.08M in 2018Q4, according to the filing. It also reduced its holding in Dollar Tree Inc (NASDAQ:DLTR) by 3,941 shares in the quarter, leaving it with 3,369 shares, and cut its stake in Select Sector Spdr Tr (XLY).

More important recent VeriSign, Inc. (NASDAQ:VRSN) news were published by: Nasdaq.com which released: “FDN, EBAY, VRSN, VEEV: Large Outflows Detected at ETF – Nasdaq” on March 19, 2019, also Businesswire.com published article titled: “Internet Grows to 348.7 Million Domain Name Registrations in the Fourth Quarter of 2018 – Business Wire”, Nasdaq.com published: “First Trust Dow Jones Internet Index Fund Experiences Big Inflow – Nasdaq” on April 10, 2019. More interesting news about VeriSign, Inc. (NASDAQ:VRSN) was released by: Nasdaq.com and their article: “Notable ETF Inflow Detected – FDN, EBAY, TWTR, VRSN – Nasdaq” with publication date: March 27, 2019.

Investors sentiment increased to 1.07 in 2018 Q4. Its up 0.01, from 1.06 in 2018Q3. It increased, as 34 investors sold ALNY shares while 70 reduced holdings. 28 funds opened positions while 83 raised stakes. 89.04 million shares or 2.44% more from 86.92 million shares in 2018Q3 were reported. Maverick Cap Limited, a Texas-based fund reported 2.80 million shares. Winslow Evans & Crocker, a Massachusetts-based fund reported 1,510 shares. Amp Ltd has invested 0.01% of its portfolio in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Fred Alger invested 0.03% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). State Of Alaska Department Of Revenue, Alaska-based fund reported 10,823 shares. Mutual Of America Cap Mngmt Ltd holds 0% or 1,935 shares in its portfolio. Metropolitan Life Ins Commerce has 0.01% invested in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) for 6,336 shares. 41,969 are owned by Bnp Paribas Arbitrage Sa. Sumitomo Mitsui Asset Mgmt owns 21,505 shares. State Of Wisconsin Investment Board, Wisconsin-based fund reported 35,237 shares. 79 were reported by Meeder Asset Management. Dimensional Fund Advsr Lp, Texas-based fund reported 225,148 shares. State Street reported 2.40 million shares or 0.02% of all its holdings. Frontier Cap Co Lc holds 0.12% in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) or 197,869 shares. Citigroup Incorporated accumulated 79,047 shares or 0.01% of the stock.

More notable recent Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) news were published by: Seekingalpha.com which released: “Sanofi and Alnylam wrap up research and option phase of collaboration – Seeking Alpha” on April 09, 2019, also Nasdaq.com with their article: “Why Is Alnylam (ALNY) Up 3.1% Since Last Earnings Report? – Nasdaq” published on March 09, 2019, Seekingalpha.com published: “UBS likes Lilly in premarket analyst action – Seeking Alpha” on January 23, 2019. More interesting news about Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) were released by: Nasdaq.com and their article: “Alnylam’s (ALNY) Impressive Pipeline Drives Share Price – Nasdaq” published on March 18, 2019 as well as Nasdaq.com‘s news article titled: “First Week of ALNY September 20th Options Trading – Nasdaq” with publication date: January 25, 2019.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.